A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- New cancer treatment developed at Yaleon October 15, 2019 at 7:55 am
The ground-breaking new system could theoretically be used to target different types of cancer, and what’s important is that it offers an option of treatment for those cancers resistant to ...
- Beyonce's Dad Puts Spotlight on Male Breast Canceron October 15, 2019 at 7:48 am
according to a new review Yadav and colleagues conducted of nearly 11,000 men with breast cancer. Because of this, treatment options for men are largely constrained to those developed for women, Yadav ...
- Drug shortage to affect children with canceron October 15, 2019 at 7:10 am
Vincristine, an important drug that serves as the backbone of treatment for most childhood cancers, including leukemias, lymphomas and brain tumors, has become scarce, and doctors are warning that ...
- Novartis, following fellow cancer drug makers, turns to TV advertising with new Piqray campaignon October 15, 2019 at 6:51 am
Novartis is joining a group of drugmakers already advertising cancer treatments on TV with the launch of its Piqray campaign. The first work for metastatic breast cancer (MBC) therapy Piqray includes ...
- Research on cell division provides new clues to how a common cancer treatment workson October 15, 2019 at 6:20 am
Now, Rockefeller scientists present a new way of understanding how Taxol works—and why it may not work in some cancer cells. Their findings might point to new ways of predicting which patients are ...
- Breaking the stroma barrier: Study shows a new way to hit cancer with radiationon October 15, 2019 at 5:40 am
Patients with pancreatic cancer often receive chemotherapy or radiation therapy, which are not always effective and can have toxic side effects. In a collaborative research between Osaka University ...
- Cancer Treatment Drugs Market 2019, Global Trends, Opportunity and Growth Analysis Forecast by 2024on October 15, 2019 at 1:42 am
WiseGuyReports.com adds “Cancer Treatment Drugs Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database. This report provides in ...
- NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatmentson October 14, 2019 at 12:27 pm
The company is developing a diverse portfolio of new cancer treatments that aim to perfect the process of T-cell activation and direction in the body. Tmunity has 14 therapies in its pipeline in ...
- Cancer Data Provides Insights into Treatment, Diagnosis Trendson October 14, 2019 at 6:34 am
Researchers outlined mortality and incident trends for each selected cancer and characterized the resulting “signatures.” For some cancers, such as Hodgkin’s lymphoma and chronic myeloid leukemia (CML ...
via Bing News